Amigal
Navigation Links
Amigal in Medical Technology
Agency Supports Amigal Move to Phase 3; Eligible for Accelerated Approval; Final Global Regulatory Plan Expected by Year End
CRANBURY, N.J., Aug. 4 /PRNewswire-FirstCall/ -- Amicus Therapeutics
(Nasdaq: FOLD ), a biopharmaceutical company developing small molecule,
orally-administere...
... Multiple Clinical Milestones throughout the Year; amigal to Initiate Phase 3 Global Development in Second Q...ire HGT), plans to initiate Phase 3 development of amigal for the treatment of Fabry disease in the second q...and CEO. CLINICAL PROGRAM ADVANCEMENTS amigal (migalastat hydrochloride) for the treatment of Fa...
Amicus Therapeutics Presents Data From Preclinical and Phase 1 Studies of Amigal for Fabry Disease
Studies in Mice Show Reduction of Enzyme Substrate CRANBURY, N.J., March 19, 2007 /PRNewswire/ -- Amicus Therapeutics, a biopharmaceutical company developing small-molecule, orally administered pharmacological chaperones for the treatment of human genetic diseases, announced today that the Company...Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) for the Treatment of Fabry Disease
...mpany is eligible to seek Accelerated Approval for amigal according to Subpart H regulations. The Company ha...micus stated, "The start of our Phase 3 trial with amigal is a major milestone for Amicus and highlights our...essful Phase 3 study. We continue to believe that amigal may be an important treatment option for patients ...Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
...ting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera for the treatment of Gaucher disease and AT2220 for the treatm...... Multiple Clinical Milestones throughout the Year; amigal to Initiate Phase 3 Global Development in Second Q...ire HGT), plans to initiate Phase 3 development of amigal for the treatment of Fabry disease in the second q...and CEO. CLINICAL PROGRAM ADVANCEMENTS amigal (migalastat hydrochloride) for the treatment of Fa...
Amicus Therapeutics Announces Second Quarter 2008 Financial Results
...meeting with the FDA related to our development of amigal for the treatment of Fabry Disease," said John F. ...ccessfully completed an End of Phase 2 meeting for amigal with the U.S. Food and Drug Administration (FDA). ...e Company plans to initiate Phase 3 development of amigal in the first half of 2009. In parallel with the ...Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
...ks and uncertainties inherent in the business of Amicus, including, without limitation: the effect of the completion of the Phase 2 clinical trial for amigal for the treatment of Fabry disease, the plans for the Phase 3 clinical trial for Amigal, the Phase II clinical trials for Plicera(TM) for the treatmen...Amigal in Biological Technology
Amicus Therapeutics Announces Second Quarter 2009 Financial Results
...cant achievement for Amicus with our lead program, amigal for Fabry disease, entering Phase 3 development." ...sease." Clinical Program Updates amigal (TM) (migalastat hydrochloride) for the treatme...mpany is eligible to seek Accelerated Approval for amigal according to Subpart H regulations. Amicus has beg....... Preliminary Results: Treatment with amigal was generally well-tolerated, with no drug-related...rrhea. Subjects identified as responders to amigal at the completion of the Phase 2 studies continued...he FDA supports a Phase 3 clinical trial comparing amigal to placebo based on a surrogate primary endpoint o...
Publication of Shire plc's Annual Report 2008
...t received the rights to three compounds, PLICERA, amigal and AT2220, in markets outside the US. PLIC...ights to PLICERA in markets outside the US. amigal (HGT-3310 for the treatment Fabry disease) amigal is an orally-administered, small molecule pharmaco...Amicus Therapeutics Announces Change to Board of Directors
...ting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera for the treatment of Gaucher disease and AT2220 for the treatm...Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results
...e Company plans to initiate Phase 3 development of amigal for the treatment of Fabry disease in the second q...he FDA supports a Phase 3 clinical trial comparing amigal to placebo based on a surrogate primary endpoint o...al designed to evaluate the safety and efficacy of amigal versus enzyme replacement therapy (ERT) in Fabry p...Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
...ting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera for the treatment of Gaucher disease and AT2220 for the treatm...Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
...ing lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera for the treatment of Gaucher disease and AT2220 for the treatm...Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
...ting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera for the treatment of Gaucher disease and AT2220 for the treatm...Amicus Therapeutics Announces Third Quarter 2008 Financial Results
...yments." Program Advancements Fabry Disease: amigal (migalastat hydrochloride) is an investigational, ...Company expects to initiate Phase 3 development of amigal in the first half of 2009. In addition, 23 of th...s. Amicus has completed Phase 2 clinical trials of amigal for the treatment of Fabry disease and is conducti...Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
...ting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera for the treatment of Gaucher disease and AT2220 for the treatm...Other TagsRIBAOther Contentsdaydaydaydaydaydaydaydaydayrosacearotavirusrotavirusrotavirusrotavirusroseolacuffcuffcuffrotatorrotatorrotatorroundwormsroundworms
HVADRB1OligotypingPhenosenseKininogenfingernailsNeutralizationAgglutinationHHV6GestationisHHTTimePCRRIBAChronicwith
(Date:12/15/2009)... risk, research finds , , TUESDAY, Dec. 15 (HealthDay News) ... regulates appetite, may guard against Alzheimer,s disease, new research ... may be one of many agents that we use ... study author Dr. Sudha Seshadri, an associate professor of ... may be one of many markers that we measure ...
(Date:12/15/2009)... lower strength than needed for protection, CDC says, , , ... doses of H1N1 swine flu vaccine have been recalled ... some potency, federal health officials said Tuesday. , According ... the company,s routine testing of the vaccine for children ... four batches had lower than required potency levels. "This ...
(Date:12/15/2009)... Prostate cancer tests promised but not delivered ... Network calls on Congress to ensure that healthcare ... benefit currently required of insurance companies in 37 ... for those segments of the population and individuals ... American men and men who have a family ...
(Date:12/15/2009)... Knowledge Networks is ... and bio-tech research market with the acquisition ... past 11 years CMR has built and ... (PCN®), which now includes 70,000 U.S. physicians, ... care and hard-to-reach specialties. The Mount-Arlington, ...
(Date:12/15/2009)... N.Y., Dec. 15 Team In Training ... charity sports training program, has reached ... support blood cancer research and patient services. ,, ... the pre-eminent charity endurance sports training program, preparing ... half marathon, triathlon, 100-mile century cycle ride or ...
Breaking Medicine News(10 mins):Health News:Fat Hormone May Protect Against Alzheimer's 2Health News:Fat Hormone May Protect Against Alzheimer's 3Health News:Large Recall of Children's Swine Flu Vaccine 2Health News:Men's Health Network Calls on Congress to Complete President Obama's Promise on Health Care Reform 2Health News:Knowledge Networks Expands in Pharma Research With Acquisition of CMR 2Health News:$1 Billion - For Charity! 2Health News:$1 Billion - For Charity! 3(Date:12/15/2009)... 2009 Economics, environmental impacts, social dynamics, and ... the overall success of an agroecosystem. Positive or ... forcing individuals and social groups to continuously adapt ... , Experiential learning theory suggests that knowledge ... experiences. Such lessons are especially valuable for environmental ...
(Date:12/15/2009)... American researchers found the fossil remains of a whale, 4.5 ... for the first time, the results of the decay and ... cetacean, possibly a baleen whale from the Mysticeti group. , ... remains of a whale from the Lower Pliocene (five million ... is the first time that the results of the processes ...
(Date:12/15/2009)... Group, a leading real-time and embedded technology engineering services ... three high school teams for the 2010 season of ... ). ,, The PTR Group will provide funding to ... The teams from Atholton HS in Columbia, MD, Rockwall ... Vienna, VA all have direct mentorship from engineers in ...
Breaking Biology News(10 mins):Experiential learning teaches change and adaptation 2Story of 4.5 million-year-old whale unveiled in Huelva 2Story of 4.5 million-year-old whale unveiled in Huelva 3The PTR Group Announces Financial and Technical Support to US FIRST Robotics Competition Teams 2Louisiana 26apos 3Bs TCA Cellular Therapy 26apos 3Bs Findings Reported at World Stem Cell Summit Patients 26apos 3B Legs Saved from Amputation Usin 58110 1Louisiana 26apos 3Bs TCA Cellular Therapy 26apos 3Bs Findings Reported at World Stem Cell Summit Patients 26apos 3B Legs Saved from Amputation Usin 58110 2Louisiana 26apos 3Bs TCA Cellular Therapy 26apos 3Bs Findings Reported at World Stem Cell Summit Patients 26apos 3B Legs Saved from Amputation Usin 58110 3Kayentis the Leading Provider of the Unique 26quot 3BPaper Based e Trial 26quot 3B Solution has been Retained for Six New Clinical Studies in the U 58106 1Kayentis the Leading Provider of the Unique 26quot 3BPaper Based e Trial 26quot 3B Solution has been Retained for Six New Clinical Studies in the U 58106 2New stove dramatically improves lung health in Mexican women 58102 1New stove dramatically improves lung health in Mexican women 58102 2New stove dramatically improves lung health in Mexican women 58102 3| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |